<?xml version='1.0' encoding='utf-8'?>
<document id="29415190"><sentence text="Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine."><entity charOffset="86-98" id="DDI-PubMed.29415190.s1.e0" text="Dolutegravir" /><entity charOffset="116-125" id="DDI-PubMed.29415190.s1.e1" text="Isoniazid" /><entity charOffset="130-141" id="DDI-PubMed.29415190.s1.e2" text="Rifapentine" /><pair ddi="false" e1="DDI-PubMed.29415190.s1.e0" e2="DDI-PubMed.29415190.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29415190.s1.e0" e2="DDI-PubMed.29415190.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29415190.s1.e0" e2="DDI-PubMed.29415190.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29415190.s1.e1" e2="DDI-PubMed.29415190.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29415190.s1.e1" e2="DDI-PubMed.29415190.s1.e2" /></sentence><sentence text="Once-weekly isoniazid and rifapentine for 3 months is a treatment option in persons with human immunodeficiency virus and latent tuberculosis infection"><entity charOffset="12-21" id="DDI-PubMed.29415190.s2.e0" text="isoniazid" /><entity charOffset="26-37" id="DDI-PubMed.29415190.s2.e1" text="rifapentine" /><pair ddi="false" e1="DDI-PubMed.29415190.s2.e0" e2="DDI-PubMed.29415190.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29415190.s2.e0" e2="DDI-PubMed.29415190.s2.e1" /></sentence><sentence text=" This study aimed to examine pharmacokinetic drug-drug interactions between this regimen and dolutegravir, a first-line antiretroviral medication"><entity charOffset="93-105" id="DDI-PubMed.29415190.s3.e0" text="dolutegravir" /></sentence><sentence text="" /><sentence text="This was a single-center, open-label, fixed-sequence, drug-drug interaction study in healthy volunteers" /><sentence text=" Subjects received oral dolutegravir 50 mg once daily alone (days 1-4) and concomitantly with once-weekly isoniazid 900 mg, rifapentine 900 mg, and pyridoxine 50 mg (days 5-19)"><entity charOffset="24-36" id="DDI-PubMed.29415190.s6.e0" text="dolutegravir" /><entity charOffset="106-115" id="DDI-PubMed.29415190.s6.e1" text="isoniazid" /><entity charOffset="124-135" id="DDI-PubMed.29415190.s6.e2" text="rifapentine" /><entity charOffset="148-158" id="DDI-PubMed.29415190.s6.e3" text="pyridoxine" /><pair ddi="false" e1="DDI-PubMed.29415190.s6.e0" e2="DDI-PubMed.29415190.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29415190.s6.e0" e2="DDI-PubMed.29415190.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29415190.s6.e0" e2="DDI-PubMed.29415190.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29415190.s6.e0" e2="DDI-PubMed.29415190.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29415190.s6.e1" e2="DDI-PubMed.29415190.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29415190.s6.e1" e2="DDI-PubMed.29415190.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29415190.s6.e1" e2="DDI-PubMed.29415190.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29415190.s6.e2" e2="DDI-PubMed.29415190.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29415190.s6.e2" e2="DDI-PubMed.29415190.s6.e3" /></sentence><sentence text=" Dolutegravir concentrations were measured on days 4, 14, and 19, and rifapentine, 25-desacetyl-rifapentine, and isoniazid concentrations were measured on day 19"><entity charOffset="1-13" id="DDI-PubMed.29415190.s7.e0" text="Dolutegravir" /><entity charOffset="70-81" id="DDI-PubMed.29415190.s7.e1" text="rifapentine" /><entity charOffset="83-107" id="DDI-PubMed.29415190.s7.e2" text="25-desacetyl-rifapentine" /><entity charOffset="113-122" id="DDI-PubMed.29415190.s7.e3" text="isoniazid" /><pair ddi="false" e1="DDI-PubMed.29415190.s7.e0" e2="DDI-PubMed.29415190.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29415190.s7.e0" e2="DDI-PubMed.29415190.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29415190.s7.e0" e2="DDI-PubMed.29415190.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29415190.s7.e0" e2="DDI-PubMed.29415190.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29415190.s7.e1" e2="DDI-PubMed.29415190.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29415190.s7.e1" e2="DDI-PubMed.29415190.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29415190.s7.e1" e2="DDI-PubMed.29415190.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29415190.s7.e2" e2="DDI-PubMed.29415190.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29415190.s7.e2" e2="DDI-PubMed.29415190.s7.e3" /></sentence><sentence text=" Cytokines and antidrug antibodies to isoniazid and rifapentine were examined at select time points"><entity charOffset="38-47" id="DDI-PubMed.29415190.s8.e0" text="isoniazid" /><entity charOffset="52-63" id="DDI-PubMed.29415190.s8.e1" text="rifapentine" /><pair ddi="false" e1="DDI-PubMed.29415190.s8.e0" e2="DDI-PubMed.29415190.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29415190.s8.e0" e2="DDI-PubMed.29415190.s8.e1" /></sentence><sentence text="" /><sentence text="The study was terminated following the development of flu-like syndrome and elevated aminotransferase levels in 2 of 4 subjects after the third isoniazid-rifapentine dose" /><sentence text=" Markedly elevated levels of interferon-Î³, CXCL10, C-reactive protein, and other cytokines were temporally associated with symptoms" /><sentence text=" Antidrug antibodies were infrequently detected" /><sentence text=" Dolutegravir area under the curve (AUC) was decreased by 46% (90% confidence interval, 27-110%; P = "><entity charOffset="1-13" id="DDI-PubMed.29415190.s13.e0" text="Dolutegravir" /></sentence><sentence text="13) on day 14" /><sentence text=" Rifapentine and 25-desacetyl rifapentine levels on day 19 were comparable to reference data, whereas isoniazid AUCs were approximately 67%-92% higher in the subjects who developed toxicities"><entity charOffset="1-12" id="DDI-PubMed.29415190.s15.e0" text="Rifapentine" /><entity charOffset="17-41" id="DDI-PubMed.29415190.s15.e1" text="25-desacetyl rifapentine" /><pair ddi="false" e1="DDI-PubMed.29415190.s15.e0" e2="DDI-PubMed.29415190.s15.e0" /><pair ddi="false" e1="DDI-PubMed.29415190.s15.e0" e2="DDI-PubMed.29415190.s15.e1" /></sentence><sentence text="" /><sentence text="The combined use of dolutegravir with once-weekly isoniazid-rifapentine resulted in unexpected and serious toxicities that were mediated by endogenous cytokine release"><entity charOffset="20-32" id="DDI-PubMed.29415190.s17.e0" text="dolutegravir" /><entity charOffset="60-71" id="DDI-PubMed.29415190.s17.e1" text="rifapentine" /><pair ddi="false" e1="DDI-PubMed.29415190.s17.e0" e2="DDI-PubMed.29415190.s17.e0" /><pair ddi="false" e1="DDI-PubMed.29415190.s17.e0" e2="DDI-PubMed.29415190.s17.e1" /></sentence><sentence text=" Additional investigations are necessary to examine the safety and efficacy of coadministering these medications" /><sentence text="" /><sentence text="NCT02771249" /><sentence text="" /></document>